SpringWorks Therapeutics Inc. has a potentially significant market opportunity with positive data in hand from its Phase IIb ReNeu trial of mirdametinib in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), compared with existing options that are only available for pediatric patients.
SpringWorks announced the results of the trial on 16 November, stating that it plans to seek US Food and Drug Administration for the drug, a MEK inhibitor, during the first...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?